Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Anacor Pharmaceuticals, Inc. (“Anacor”) (NASDAQ: ANAC) concerning the merger with Pfizer, Inc. Under the terms of the agreement, valued at approximately $5.2 billion, Anacor shareholders will only receive $99.25 in cash per share held.

If you are an affected investor, and you want to learn more about the investigation or if you have information that you believe would be helpful to our investigation of the fairness of the proposed transaction, contact Willie Briscoe at The Briscoe Law Firm, PLLC via email at shareholders@thebriscoelawfirm.com, Patrick Powers at Powers Taylor LLP via e-mail at shareholder@powerstaylor.com or by calling toll free at (877) 728-9607. There is no cost or fee to you.

The investigation centers on whether Anacor’s Board of Directors is acting in the shareholders’ best interests, whether the board is properly negotiating a higher share price for the shareholders, and whether the board has employed an adequate process to review and act on the proposed transaction.

The Briscoe Law Firm, PLLC is a full service business litigation and shareholder rights advocacy firm with more than 20 years of experience in complex litigation and transactional matters.

Powers Taylor LLP is a boutique litigation law firm that handles a variety of complex business litigation matters, including claims of investor and stockholder fraud, shareholder oppression, shareholder derivative suits, and security class actions.

The Briscoe Law Firm, PLLCWillie Briscoe, 877-728-9607shareholders@thebriscoelawfirm.comorPowers Taylor LLPPatrick Powers, 877-728-9607shareholder@powerstaylor.com

Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC)
Historical Stock Chart
Von Dez 2024 bis Jan 2025 Click Here for more Anacor Pharmaceuticals, Inc. Charts.
Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC)
Historical Stock Chart
Von Jan 2024 bis Jan 2025 Click Here for more Anacor Pharmaceuticals, Inc. Charts.